Table 6.12Evidence profile for trihexyphenidyl compared with placebo in children with spasticity of different severities; functioning assessment

Number of studiesNumber of participantsEffectQuality
TrihexyphenidylPlaceboRelative

(95% CI)
Absolute

(95% CI)
Mean QUEST score (better indicated by higher values)
1 study (Rice 2008)16a16b--cLow
Mean GAS score (better indicated by higher values)
1 study (Rice 2008)16d16e--fVery low
Mean COPM-P score (better indicated by higher values)
1 study (Rice 2008)16g16h--iVery low

CI confidence interval, COPM-P Canadian Occupational Performance Measure – Performance, GAS Goal Attainment Scaling, QUEST Quality of Upper Extremity Skills Test

a

Baseline mean QUEST score: 15.3 (-0.1 to 30.7). Final score 13.5 (1.4 to 25.5)

b

Baseline mean QUEST score: 15.3 (-0.1 to 30.7). Final score 15.1 (2.8 to 27.4)

c

Reported mean difference = -1.6 (-6.3 to 3.1)

d

Baseline mean GAS score: 20.0. Final score 39.3 (31.8 to 46.8)

e

Baseline mean GAS score: 20.0. Final score 33.3 (27.4 to 39.1)

f

Reported mean difference = 6.8 (-3.7 to 17.5)

g

Baseline mean COPM score (performance): 2.6 (2.2 to 3.0). Final score 4.4 (3.6 to 5.3)

h

Baseline mean COPM score (performance): 2.6 (2.2 to 3.0). Final score 3.8 (3.0 to 4.7)

i

Reported mean difference = 0.8 (-0.5 to 2.0)

See the complete GRADE Table K.6.12 which accompanies this abbreviated version.

Baseline mean QUEST score: 15.3 (-0.1 to 30.7). Final score 13.5 (1.4 to 25.5)

Baseline mean QUEST score: 15.3 (-0.1 to 30.7). Final score 15.1 (2.8 to 27.4)

Reported mean difference = -1.6 (-6.3 to 3.1)

Baseline mean GAS score: 20.0. Final score 39.3 (31.8 to 46.8)

Baseline mean GAS score: 20.0. Final score 33.3 (27.4 to 39.1)

Reported mean difference = 6.8 (-3.7 to 17.5)

Baseline mean COPM score (performance): 2.6 (2.2 to 3.0). Final score 4.4 (3.6 to 5.3)

Baseline mean COPM score (performance): 2.6 (2.2 to 3.0). Final score 3.8 (3.0 to 4.7)

Reported mean difference = 0.8 (-0.5 to 2.0)

From: 6, Oral drugs

Cover of Spasticity in Children and Young People with Non-Progressive Brain Disorders
Spasticity in Children and Young People with Non-Progressive Brain Disorders: Management of Spasticity and Co-Existing Motor Disorders and Their Early Musculoskeletal Complications.
NICE Clinical Guidelines, No. 145.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2012 Jul.
Copyright © 2012, National Collaborating Centre for Women's and Children's Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.